MA62049B1 - Composé de dégradation dans un médicament - Google Patents

Composé de dégradation dans un médicament

Info

Publication number
MA62049B1
MA62049B1 MA62049A MA62049A MA62049B1 MA 62049 B1 MA62049 B1 MA 62049B1 MA 62049 A MA62049 A MA 62049A MA 62049 A MA62049 A MA 62049A MA 62049 B1 MA62049 B1 MA 62049B1
Authority
MA
Morocco
Prior art keywords
medicament
brimonidine
carbachol
impurities
less
Prior art date
Application number
MA62049A
Other languages
English (en)
Inventor
Rhett Mead SCHIFFMAN
Bruce Alan FIRESTONE
Original Assignee
Visus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visus Therapeutics, Inc. filed Critical Visus Therapeutics, Inc.
Publication of MA62049B1 publication Critical patent/MA62049B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des formulations ophtalmiques comprenant du carbachol, de la brimonidine et moins de 5 % d'une ou de plusieurs impuretés, des procédés de préparation de formulations ophtalmiques comprenant du carbachol, de la brimonidine et moins de 5 % d'une ou de plusieurs impuretés, ainsi que des méthodes de traitement de la presbytie et d'autres états ophtalmiques par administration de formulations ophtalmiques comprenant du carbachol, de la brimonidine et moins de 5 % d'une ou de plusieurs impuretés.
MA62049A 2020-11-02 2021-11-02 Composé de dégradation dans un médicament MA62049B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063108720P 2020-11-02 2020-11-02
US202163162367P 2021-03-17 2021-03-17
US202163257024P 2021-10-18 2021-10-18
EP21887770.2A EP4236932B1 (fr) 2020-11-02 2021-11-02 Composé de dégradation dans un médicament
PCT/US2021/057720 WO2022094462A1 (fr) 2020-11-02 2021-11-02 Composé de dégradation dans un médicament

Publications (1)

Publication Number Publication Date
MA62049B1 true MA62049B1 (fr) 2026-02-27

Family

ID=81383327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62049A MA62049B1 (fr) 2020-11-02 2021-11-02 Composé de dégradation dans un médicament

Country Status (18)

Country Link
US (2) US20230390284A1 (fr)
EP (1) EP4236932B1 (fr)
JP (1) JP2023548336A (fr)
KR (1) KR20230104645A (fr)
AU (1) AU2021369566A1 (fr)
CA (1) CA3195784A1 (fr)
CL (1) CL2023001258A1 (fr)
CO (1) CO2023007133A2 (fr)
CR (1) CR20230190A (fr)
DK (1) DK4236932T3 (fr)
FI (1) FI4236932T3 (fr)
HR (1) HRP20260130T1 (fr)
LT (1) LT4236932T (fr)
MA (1) MA62049B1 (fr)
MX (1) MX2023005031A (fr)
PT (1) PT4236932T (fr)
TW (1) TW202233170A (fr)
WO (1) WO2022094462A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117571883B (zh) * 2024-01-15 2024-03-19 四川智强医药科技开发有限公司 一种酒石酸溴莫尼定滴眼液的质量检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980818B2 (en) * 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
EP2525793B1 (fr) * 2010-01-21 2018-09-05 Allergan, Inc. Agoniste alpha-2-adrénergique ayant un effet de réduction de la pression intra-oculaire de longue durée
WO2016205068A1 (fr) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Compositions stables au stockage et procédés de traitement d'erreurs de réfraction de l'œil
EP3429584A4 (fr) * 2016-03-17 2019-11-13 Presbyopia Therapies, LLC Compositions et méthodes de traitement de la presbytie
US20200345542A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
US20220257593A1 (en) 2019-06-10 2022-08-18 Visus Therapeutics, Inc. Carabachol-bromonidine formulation to enhance anti-presbyopia effects

Also Published As

Publication number Publication date
MX2023005031A (es) 2023-06-29
EP4236932B1 (fr) 2026-01-07
EP4236932A1 (fr) 2023-09-06
JP2023548336A (ja) 2023-11-16
US20240100046A1 (en) 2024-03-28
AU2021369566A1 (en) 2023-06-22
DK4236932T3 (da) 2026-02-09
EP4236932A4 (fr) 2024-10-09
LT4236932T (lt) 2026-03-25
HRP20260130T1 (hr) 2026-03-27
WO2022094462A1 (fr) 2022-05-05
PT4236932T (pt) 2026-02-23
CL2023001258A1 (es) 2023-12-22
US20230390284A1 (en) 2023-12-07
KR20230104645A (ko) 2023-07-10
FI4236932T3 (fi) 2026-02-12
CA3195784A1 (fr) 2022-05-05
CR20230190A (es) 2023-09-06
TW202233170A (zh) 2022-09-01
AU2021369566A9 (en) 2025-04-10
CO2023007133A2 (es) 2023-06-20

Similar Documents

Publication Publication Date Title
EP4491229A3 (fr) Arn codant administré dans l'espace suprachoroïdien dans le traitement de maladies ophtalmiques
ZA202109010B (en) Compounds and methods for the treatment of covid-19
MX2019015578A (es) Metodos para tratar la enfermedad de huntington.
WO2016172712A3 (fr) Composition ophtalmique
EP4233861A3 (fr) Compositions pour le traitement du tremblement essentiel
MY169816A (en) Ophthalmic solution comprising diquafosol
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
WO2018111315A8 (fr) DÉRIVÉS ÉNONE DE PYRIMIDINE TRICYCLIQUE POUR L'INHIBITION DE RORγ ET D'AUTRES UTILISATIONS
EP4324454A3 (fr) Agents de reticulation et procedes associes
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
WO2022247920A9 (fr) Composé quinolinamine, son procédé de préparation et son utilisation dans des produits pharmaceutiques
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
WO2023081830A3 (fr) Compositions et traitements à base de nirogacestat
MX2024000701A (es) Metodos de tratamiento de la enfermedad de alzheimer.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2022003845A (es) Tratamientos cognitivos medicinales.
CR20230190A (es) Compuesto degradante en un medicamento
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
EA202092472A1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
PH12021551975A1 (en) Use of vibegron to treat overactive bladder
WO2020247819A3 (fr) Méthode de traitement à l'aide de modulateurs de l'acide aminolévulinique synthase 2 (alas2)
AU2020299145A8 (en) Compositions and methods for treating eye diseases